Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity

Internal Medicine Journal

Volumn 42, Issue 4, 2012, Pages 374-380

  Algotar, A M ^a,b   Thompson, P A ^a,b   Ranger Moore, J ^b   Stratton, M S ^a   Hsu, C H ^a,b   Ahmann, F R ^a,b   Nagle, R B ^a,b   Stratton, S P ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Aspirin; Prostate cancer progression; PSA velocity; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; CHROMOGRANIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BODY MASS; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; HUMAN; LONGITUDINAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SMOKING;

ADULT; AGED; ASPIRIN; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; KALLIKREINS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 84859819988     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02473.x     Document Type: Article

References (26)

1. ACS. Cancer Facts and Figures. Atlanta: ACS; 2010.
2. Lamb DS, Slaney D, Smart R, Nacey JN, Russell G, Scott B etal. Prostate cancer: the new evidence base for diagnosis and treatment. Pathology 2007; 39: 537-44.
3. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A etal. Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713-19.
4. Chodak GW, Warren KS. Watchful waiting for prostate cancer: a review article. Prostate Cancer Prostatic Dis 2006; 9: 25-9.
5. Steuber T, Helo P, Lilja H. Circulating biomarkers for prostate cancer. World J Urol 2007; 25: 111-19.
6. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006; 106: 320-8.
7. Bangma CH, Roemeling S, Schroder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007; 25: 3-9.
8. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J etal. Human prostate cancer risk factors. Cancer 2004; 101(10 Suppl): 2371-490.
9. Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH etal. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res 2010; 3: 1035-43.
10. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-74.
11. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608-15.
12. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004; 90: 93-9.
13. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM etal. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005; 14: 390-6.
14. Sutcliffe S, Platz EA. Inflammation in the etiology of prostate cancer: an epidemiologic perspective. Urol Oncol 2007; 25: 242-9.
15. Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR etal. Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. Prostate 2010; 70: 883-8.
16. Hickey K, Do KA, Green A. Smoking and prostate cancer. Epidemiol Rev 2001; 23: 115-25.
17. Giovannucci E, Rimm EB, Ascherio A, Colditz GA, Spiegelman D, Stampfer MJ etal. Smoking and risk of total and fatal prostate cancer in United States health professionals. Cancer Epidemiol Biomarkers Prev 1999; 8(4 Pt 1): 277-82.
18. Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005; 47: 16-21.
19. Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006; 106: 1047-53.
20. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A etal. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 2810-16.
21. Whitson JM, Carroll PR. Active surveillance for early-stage prostate cancer: defining the triggers for intervention. J Clin Oncol 2010; 28: 2807-9.
22. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294: 440-7.
23. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-35.
24. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI etal. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98: 1521-7.
25. Rozhansky F, Chen MH, Cox MC, Dahut W, Figg WD, D'Amico AV. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 2006; 106: 63-7.
26. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-31.